216 related articles for article (PubMed ID: 30936097)
1. Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.
Saini V; Ammerman NC; Chang YS; Tasneen R; Chaisson RE; Jain S; Nuermberger E; Grosset JH
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30936097
[TBL] [Abstract][Full Text] [Related]
2. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
[TBL] [Abstract][Full Text] [Related]
3. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
[TBL] [Abstract][Full Text] [Related]
4. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
Zhang T; Li SY; Williams KN; Andries K; Nuermberger EL
Am J Respir Crit Care Med; 2011 Sep; 184(6):732-7. PubMed ID: 21659613
[TBL] [Abstract][Full Text] [Related]
5. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
[TBL] [Abstract][Full Text] [Related]
6. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
Tasneen R; Garcia A; Converse PJ; Zimmerman MD; Dartois V; Kurbatova E; Vernon AA; Carr W; Stout JE; Dooley KE; Nuermberger EL
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0239821. PubMed ID: 35315690
[TBL] [Abstract][Full Text] [Related]
7. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Williams K; Minkowski A; Amoabeng O; Peloquin CA; Taylor D; Andries K; Wallis RS; Mdluli KE; Nuermberger EL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3114-20. PubMed ID: 22470112
[TBL] [Abstract][Full Text] [Related]
8. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
Zhang T; Zhang M; Rosenthal IM; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2009 Dec; 180(11):1151-7. PubMed ID: 19729664
[TBL] [Abstract][Full Text] [Related]
9. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
[TBL] [Abstract][Full Text] [Related]
10. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.
Tyagi S; Ammerman NC; Li SY; Adamson J; Converse PJ; Swanson RV; Almeida DV; Grosset JH
Proc Natl Acad Sci U S A; 2015 Jan; 112(3):869-74. PubMed ID: 25561537
[TBL] [Abstract][Full Text] [Related]
11. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
Park SW; Tasneen R; Converse PJ; Nuermberger EL
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
[TBL] [Abstract][Full Text] [Related]
12. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
[TBL] [Abstract][Full Text] [Related]
13. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
Tasneen R; Li SY; Peloquin CA; Taylor D; Williams KN; Andries K; Mdluli KE; Nuermberger EL
Antimicrob Agents Chemother; 2011 Dec; 55(12):5485-92. PubMed ID: 21930883
[TBL] [Abstract][Full Text] [Related]
14. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
Dorman SE; Savic RM; Goldberg S; Stout JE; Schluger N; Muzanyi G; Johnson JL; Nahid P; Hecker EJ; Heilig CM; Bozeman L; Feng PJ; Moro RN; MacKenzie W; Dooley KE; Nuermberger EL; Vernon A; Weiner M;
Am J Respir Crit Care Med; 2015 Feb; 191(3):333-43. PubMed ID: 25489785
[TBL] [Abstract][Full Text] [Related]
15. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492
[TBL] [Abstract][Full Text] [Related]
16. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
Zhang M; Li SY; Rosenthal IM; Almeida DV; Ahmad Z; Converse PJ; Peloquin CA; Nuermberger EL; Grosset JH
Am J Respir Crit Care Med; 2011 May; 183(9):1254-61. PubMed ID: 21330452
[TBL] [Abstract][Full Text] [Related]
17. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
Lanoix JP; Betoudji F; Nuermberger E
Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
[TBL] [Abstract][Full Text] [Related]
18. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Vernon A; Burman W; Benator D; Khan A; Bozeman L
Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
[TBL] [Abstract][Full Text] [Related]
19. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
Dorman SE; Nahid P; Kurbatova EV; Goldberg SV; Bozeman L; Burman WJ; Chang KC; Chen M; Cotton M; Dooley KE; Engle M; Feng PJ; Fletcher CV; Ha P; Heilig CM; Johnson JL; Lessem E; Metchock B; Miro JM; Nhung NV; Pettit AC; Phillips PPJ; Podany AT; Purfield AE; Robergeau K; Samaneka W; Scott NA; Sizemore E; Vernon A; Weiner M; Swindells S; Chaisson RE;
Contemp Clin Trials; 2020 Mar; 90():105938. PubMed ID: 31981713
[TBL] [Abstract][Full Text] [Related]
20. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]